# OnCo record kalivir-immunotherapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/kalivir-immunotherapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "kalivir-immunotherapeutics" ;
  schema:name "KaliVir Immunotherapeutics"@en ;
  schema:description "KaliVir Immunotherapeutics engineers viruses that infect and break open cancer cells while stirring an immune response. Its lead virus, VET3-TGI, is in an early trial in advanced solid tumours, alone and with the immunotherapy atezolizumab."@en ;
  schema:url <https://onco.cc/companies/kalivir-immunotherapeutics/>, <https://kalivir.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://kalivir.com/>, <https://clinicaltrials.gov/study/NCT06444815>, <https://kalivir.com/wp-content/uploads/2026/08/KaliVir_pr-08-19-2026_Announces-Closing-of-14-Million-Series-A-Extension-Financing.pdf> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/oncolytic-virus/> .